Truist Financial
ITCI

Truist Financial’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Truist Financial’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,736
Closed -$757K – 2713
2025
Q1 		$757K Sell
5,736
-40,420
-88% -$5.04M ﹤0.01% 1652
2024
Q4 		$3.85M Buy
46,156
+268
+0.6% +$22K 0.01% 945
2024
Q3 		$3.36M Buy
45,888
+453
+1% +$34K 0.01% 1000
2024
Q2 		$3.11M Sell
45,435
-18,931
-29% -$1.31M ﹤0.01% 1070
2024
Q1 		$4.45M Buy
64,366
+342
+0.5% +$23.5K 0.01% 922
2023
Q4 		$4.59M Buy
64,024
+2,134
+3% +$123K 0.01% 892
2023
Q3 		$3.22M Buy
61,890
+1,172
+2% +$68.3K 0.01% 1016
2023
Q2 		$3.84M Buy
60,718
+751
+1% +$46.8K 0.01% 945
2023
Q1 		$3.25M Buy
59,967
+13,555
+29% +$655K 0.01% 1009
2022
Q4 		$2.46M Sell
46,412
-609
-1% -$30.5K ﹤0.01% 1104
2022
Q3 		$2.19M Buy
+47,021
New +$2.46M ﹤0.01% 1125

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Truist Financial's ITCI Position: Q2 2025 in Review

Truist Financial sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 5,736 shares — an estimated $757K sold.

Truist Financial first reported a position in ITCI in Q3 2022 and held it in 11 quarters. The position peaked at $4.59M in Q4 2023. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Truist Financial reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Truist Financial sold 5,736 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $757K.
  • Truist Financial first reported a position in Intra-Cellular Therapies Inc. in Q3 2022 and held it in 11 quarters.
  • Truist Financial's Intra-Cellular Therapies Inc. position peaked at $4.59M in Q4 2023.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Truist Financial's 13F filing for Q2 2025, filed 18 Jul 2025.